[go: up one dir, main page]

WO1999006834A3 - Procedes permettant d'identifier des molecules de liaison presentant une affinite specifique pour des ligands - Google Patents

Procedes permettant d'identifier des molecules de liaison presentant une affinite specifique pour des ligands

Info

Publication number
WO1999006834A3
WO1999006834A3 PCT/US1998/016280 US9816280W WO9906834A3 WO 1999006834 A3 WO1999006834 A3 WO 1999006834A3 US 9816280 W US9816280 W US 9816280W WO 9906834 A3 WO9906834 A3 WO 9906834A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid support
diverse population
antibody
binding molecules
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/016280
Other languages
English (en)
Other versions
WO1999006834A2 (fr
Inventor
Jeffry D Watkins
William D Huse
Herren Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Molecular Evolution Inc
Original Assignee
Ixsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ixsys Inc filed Critical Ixsys Inc
Priority to AU86913/98A priority Critical patent/AU8691398A/en
Priority to JP2000505515A priority patent/JP2004503201A/ja
Priority to EP98938377A priority patent/EP1007967A2/fr
Publication of WO1999006834A2 publication Critical patent/WO1999006834A2/fr
Publication of WO1999006834A3 publication Critical patent/WO1999006834A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un procédé permettant d'identifier une molécule de liaison présentant une affinité sélective pour un ligand. Ce procédé consiste à immobiliser, de manière sélective, une population diverse de molécules de liaison à un support solide, à placer simultanément en contact la population diverse immobilisée sur le support solide avec deux ou plusieurs ligands et à déterminer au moins une molécule de liaison qui se lie, de manière sélective, à un ou plusieurs ligands. En outre, l'invention concerne un procédé permettant d'identifier un anticorps présentant une affinité selective pour un antigène tumoral. Ce procédé consiste à immobiliser, de manière sélective, une population diverse d'anticorps sur un support solide, à placer simultanément en contact la population diverse immobilisée sur le support solide avec deux ou plusieurs antigènes tumoraux et à déterminer au moins un anticorps qui se lit, de manière sélective, avec un ou plusieurs des antigènes tumoraux. L'invention concerne également un polypeptide de liaison isolé présentant une activité sélective pour un antigène tumoral. En outre, la présente invention concerne une région de détermination de la complémentarité ou un fragment fonctionnel de cette dernière d'un anticorps sélectif pour un antigène tumoral.
PCT/US1998/016280 1997-08-04 1998-08-04 Procedes permettant d'identifier des molecules de liaison presentant une affinite specifique pour des ligands Ceased WO1999006834A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU86913/98A AU8691398A (en) 1997-08-04 1998-08-04 Methods for identifying ligand specific binding molecules
JP2000505515A JP2004503201A (ja) 1997-08-04 1998-08-04 リガンド特異的結合分子の同定方法
EP98938377A EP1007967A2 (fr) 1997-08-04 1998-08-04 Procedes permettant d'identifier des molecules de liaison presentant une affinite specifique pour des ligands

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90582597A 1997-08-04 1997-08-04
US08/905,825 1997-08-04

Publications (2)

Publication Number Publication Date
WO1999006834A2 WO1999006834A2 (fr) 1999-02-11
WO1999006834A3 true WO1999006834A3 (fr) 1999-05-14

Family

ID=25421544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/016280 Ceased WO1999006834A2 (fr) 1997-08-04 1998-08-04 Procedes permettant d'identifier des molecules de liaison presentant une affinite specifique pour des ligands

Country Status (3)

Country Link
EP (1) EP1007967A2 (fr)
AU (1) AU8691398A (fr)
WO (1) WO1999006834A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8835610B2 (en) 2009-03-05 2014-09-16 Abbvie Inc. IL-17 binding proteins
US8841417B2 (en) 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
US8895475B2 (en) 2000-12-18 2014-11-25 Robert Charles Ladner Focused libraries of genetic packages
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies
US9382535B2 (en) 2000-04-17 2016-07-05 Dyax Corp. Methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
US9592293B2 (en) 2006-09-08 2017-03-14 Abbvie Inc. Interleukin-13 binding proteins

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1025256A2 (fr) * 1997-10-09 2000-08-09 Ixsys, Incorporated Methode d'identification de ligands a liaison optimale avec un recepteur
EP1030861A4 (fr) 1997-10-31 2001-09-05 Maxygen Inc Modification du tropisme viral et de la diversite d'especes hote par recombinaison du genome viral
WO2001027327A2 (fr) 1999-10-08 2001-04-19 Protogene Laboratories, Inc. Procede et appareil destines a produire un grand nombre de reactions au moyen d'une plaque matrice
SE9903895D0 (sv) * 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
GB0008419D0 (en) * 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US9109223B2 (en) 2005-12-23 2015-08-18 Viventia Bio, Inc. Methods for generating and screening fusion protein libraries and uses thereof
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2214708A4 (fr) 2007-10-26 2011-01-12 Centocor Ortho Biotech Inc Vecteurs, cellules hôtes, procédés de production et utilisations
WO2009114815A1 (fr) 2008-03-13 2009-09-17 Dyax Corp Bibliothèques de boîtiers génétiques comprenant de nouvelles conceptions de hc cdr3
US9388510B2 (en) 2008-04-24 2016-07-12 Dyax Corp. Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
MY159667A (en) 2008-05-09 2017-01-13 Abbvie Inc Antibodies to receptor of advanced glycation end products (rage) and uses thereof
SG191625A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
TWI465250B (zh) 2009-08-29 2014-12-21 Abbvie Inc 治療用之ｄｌｌ４結合蛋白質
EP2473524A4 (fr) 2009-09-01 2013-05-22 Abbott Lab Immunoglobulines à double domaine variable et leurs utilisations
WO2011047262A2 (fr) 2009-10-15 2011-04-21 Abbott Laboratories Immunoglobulines à deux domaines variables et utilisations afférentes
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
RU2605928C2 (ru) 2010-03-02 2016-12-27 Эббви Инк. Терапевтические dll4-связывающие белки
EP4219805B1 (fr) 2010-07-16 2025-02-26 Adimab, LLC Banques d'anticorps
PE20131412A1 (es) 2010-08-03 2014-01-19 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
EP4056589A1 (fr) 2010-08-19 2022-09-14 Zoetis Belgium S.A. Anticorps anti-ngf et leur utilisation
SG187938A1 (en) 2010-08-26 2013-04-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
TW201323440A (zh) 2011-10-24 2013-06-16 Abbvie Inc 抗骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）之免疫結合物
WO2013102042A2 (fr) 2011-12-30 2013-07-04 Abbvie Inc. Protéines à double liaison spécifique dirigées contre l'il-13 et/ou l'il-17
WO2013184871A1 (fr) 2012-06-06 2013-12-12 Zoetis Llc Anticorps anti-ngf caninisés et procédés associés
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
PT2890717T (pt) 2012-08-31 2020-04-22 Immunogen Inc Ensaios de diagnóstico e kits para deteção de recetor de folato 1
CN104884472B (zh) 2012-11-01 2021-10-15 艾伯维公司 抗-vegf/dll4双重可变结构域免疫球蛋白及其用途
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
BR112015023355A8 (pt) 2013-03-14 2018-01-30 Abbott Lab antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
CN105228649B (zh) 2013-03-14 2019-01-18 雅培制药有限公司 Hcv抗原-抗体组合测定和方法以及用在其中的组合物
MX2015013166A (es) 2013-03-15 2015-12-11 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
DK3458479T3 (da) 2016-06-08 2021-02-08 Abbvie Inc Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
KR20190078648A (ko) 2016-11-16 2019-07-04 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 방법
WO2018098370A1 (fr) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. Protéines de liaison à 4-1bb et leurs utilisations
WO2018127791A2 (fr) 2017-01-06 2018-07-12 Biosion, Inc. Anticorps erbb2 et leurs utilisations
AU2017396503B2 (en) 2017-01-30 2025-02-06 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active Psoriatic arthritis
IL319561A (en) 2017-02-07 2025-05-01 Janssen Biotech Inc Anti-TNF antibodies, compositions and methods for treating active ankylosing spondylitis
WO2019025299A1 (fr) 2017-07-31 2019-02-07 F. Hoffmann-La Roche Ag Procédé d'humanisation à base de structure tridimensionnelle
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3694552A1 (fr) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anticorps anti-lap et leurs utilisations
US20190135910A1 (en) 2017-11-06 2019-05-09 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
SG11202007702UA (en) 2018-02-14 2020-09-29 Viela Bio Inc Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
JP7516250B2 (ja) 2018-03-05 2024-07-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法
CN111819197B (zh) 2018-03-12 2025-03-11 硕腾服务有限责任公司 抗ngf抗体及其方法
JP7634474B2 (ja) 2018-07-18 2025-02-21 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
BR112021005467A2 (pt) 2018-09-24 2021-06-22 Janssen Biotech, Inc. método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
TW202035445A (zh) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 抗lap抗體變異體及其用途
JP2022513094A (ja) 2018-11-20 2022-02-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ－２３特異的抗体で乾癬を治療する安全かつ有効な方法
JP2022514561A (ja) 2018-12-18 2022-02-14 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法
CN113840838A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的制造方法
WO2020183271A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de production de compositions d'anticorps anti-tnf
JP7660067B2 (ja) 2019-03-14 2025-04-10 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体組成物を生成するための製造方法
EA202192505A1 (ru) 2019-03-14 2022-03-29 Янссен Байотек, Инк. Способы получения композиций антитела к фно
KR20210141583A (ko) 2019-03-18 2021-11-23 얀센 바이오테크 인코포레이티드 항-il-12/il-23 항체를 사용한 소아 대상의 건선 치료 방법
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
JP2022536088A (ja) 2019-06-04 2022-08-12 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
EP4146273A4 (fr) 2020-05-05 2024-07-31 Janssen Biotech, Inc. Procédés de traitement de la maladie de crohn au moyen d'un anticorps spécifique anti-il23
BR112022023489A2 (pt) 2020-05-21 2023-03-14 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
CA3189402A1 (fr) 2020-07-13 2022-01-20 Janssen Biotech, Inc. Methode sure et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps specifique anti-il23
CA3190230A1 (fr) 2020-07-30 2022-02-03 Janssen Biotech, Inc. Methode de traitement du psoriasis chez des sujets pediatriques avec un anticorps anti-il12/il23
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN117203232A (zh) 2021-03-17 2023-12-08 瑞塞普托斯有限责任公司 用抗il-13抗体治疗特应性皮炎的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000295A1 (fr) * 1989-06-30 1991-01-10 Oncogen Limited Partnership Nouveaux anticorps reagissant avec les carcinomes humains
WO1995006067A1 (fr) * 1993-08-21 1995-03-02 Imperial Cancer Research Technology Limited Anticorps monoclonaux utilises pour le diagnostic et le traitement du cancer colorectal
WO1995035374A1 (fr) * 1994-06-21 1995-12-28 Dan Michael D Anticorps monoclonaux humains specifiques vis-a-vis d'antigenes de surface de gliomes, independants du cycle cellulaire
EP0699756A1 (fr) * 1994-08-04 1996-03-06 Bristol-Myers Squibb Company Anticorps BR96 mutants et équivalents fonctionnels réagissant aux carcinomes humains

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000295A1 (fr) * 1989-06-30 1991-01-10 Oncogen Limited Partnership Nouveaux anticorps reagissant avec les carcinomes humains
WO1995006067A1 (fr) * 1993-08-21 1995-03-02 Imperial Cancer Research Technology Limited Anticorps monoclonaux utilises pour le diagnostic et le traitement du cancer colorectal
WO1995035374A1 (fr) * 1994-06-21 1995-12-28 Dan Michael D Anticorps monoclonaux humains specifiques vis-a-vis d'antigenes de surface de gliomes, independants du cycle cellulaire
EP0699756A1 (fr) * 1994-08-04 1996-03-06 Bristol-Myers Squibb Company Anticorps BR96 mutants et équivalents fonctionnels réagissant aux carcinomes humains

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. YELTON ET AL.: "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis.", THE JOURNAL OF IMMUNOLOGY, vol. 155, no. 4, 15 August 1995 (1995-08-15), Baltimore, MD, USA, pages 1994 - 2004, XP002096491 *
I. SANZ ET AL.: "The smaller human VH gene families display remarkably little polymorphism.", THE EMBO JOURNAL, vol. 8, no. 12, 1 December 1989 (1989-12-01), Oxford, GB, pages 3741 - 3748, XP002096490 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382535B2 (en) 2000-04-17 2016-07-05 Dyax Corp. Methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
US8895475B2 (en) 2000-12-18 2014-11-25 Robert Charles Ladner Focused libraries of genetic packages
US9592293B2 (en) 2006-09-08 2017-03-14 Abbvie Inc. Interleukin-13 binding proteins
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8835610B2 (en) 2009-03-05 2014-09-16 Abbvie Inc. IL-17 binding proteins
US9481736B2 (en) 2009-03-05 2016-11-01 Abbvie, Inc. IL-17 binding proteins
US9481735B2 (en) 2009-03-05 2016-11-01 Abbvie Inc. IL-17 binding proteins
US8841417B2 (en) 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies

Also Published As

Publication number Publication date
AU8691398A (en) 1999-02-22
WO1999006834A2 (fr) 1999-02-11
EP1007967A2 (fr) 2000-06-14

Similar Documents

Publication Publication Date Title
WO1999006834A3 (fr) Procedes permettant d'identifier des molecules de liaison presentant une affinite specifique pour des ligands
CA2162568A1 (fr) Methode et reactif pour la mise a l'essai d'un ligand ou simultanement de plusieurs ligands dans un groupe de ligands predetermine
CA2224674C (fr) Immuno-essai et kit comportant deux reactifs qui sont reticules s'ils adherent a un echantillon a analyser
AU3684197A (en) Assay reagents and devices
DE69503903D1 (de) Positive und positive/negative zellselektion vermittelt durch peptiofreisetzung
JP2003530543A5 (fr)
CA2235269A1 (fr) Anticorps monoclonal br110 et ses utilisations
MX161338A (es) Aparato para inmunoensayos de un enlazante receptor
JP2004528574A5 (fr)
IL154000A (en) A method that uses antibodies to diagnose arthritis
ATE545019T1 (de) Mikrofluidisches extraktionsverfahren
JPH06508214A (ja) イオン捕獲ジゴキシンアッセイを実施するための方法及び試薬
WO2003046140A3 (fr) Dosage immunologique et kit de detection precoce et simultanee de marqueurs biochimiques dans l'echantillon d'un patient
EP0829723A3 (fr) Méthode de détection homogène pour la détermination de sous-populations d'un analyte
WO2003062444A3 (fr) Systemes matriciels et procedes
CA1194415A (fr) Demi-molecules d'immunoglobulines et procede de production d'anticorps hybrides
CA2411392A1 (fr) Complexes tetrameriques d'anticorps utilises pour l'inhibition du marquage non specifique des antigenes
CA2067584A1 (fr) Complexe agglutinant en tant que reactif pour le typage sanguin
CA2499355A1 (fr) Preparations, procedes et kits pour la detection d'un antigene sur une cellule et dans un melange biologique
JP2002525607A5 (fr)
WO2000037941A3 (fr) PROCEDE DE DETECTION ET/OU DE QUANTIFICATION D'UN ANTICORPS IgE SPECIFIQUE DANS UN ECHANTILLON LIQUIDE
AU687932B2 (en) A method for the determinatin of antigens or antibodies in the presence of an immune complex
CA2483408A1 (fr) Dosage en sandwich et kit
WO1999000424A3 (fr) Anticorps et autres molecules de liaison specifiques les antigenes viraux de l'hepatite b
MY137138A (en) Diagnostic reagents and preparing methods thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998938377

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998938377

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998938377

Country of ref document: EP